

European Society for Clinical Virology  
(Limited by guarantee)

Report and Financial Statements  
for the year ended 31 October 2020

**Members of Executive - Company Directors**  
**(November 1<sup>st</sup> 2019 - October 31<sup>st</sup> 2020)**

Prof. Dr. Mariet C.W. Feltkamp (President)  
Prof. Dr. Javier Buesa (Past President)  
Prof. Dr. Fausto Baldanti  
Prof. Dr. George Sourvinos  
Prof. Dr. Pamela Vallely (General Secretary)  
Prof. Dr. Heli Harvala  
Prof. Dr. Marcus Panning  
Prof. Dr. Maria São José Alexandre Nascimento

**Company Secretary**

Janina Ohnhaus, Kenes Group, Madrid Office  
Gema Casal, Kenes Group, Madrid Office

**European Society for Clinical Virology (ESCV) details**

Registered Office  
Charles Darwin House  
12 Roger Street  
London

Company limited by guarantee  
N° 04620455

Registered as a Charity in England  
N° 1099537

Inland Revenue reference:  
610 94961 19846 A 01

## **Directors' Report**

The European Society for Clinical Virology (ESCV) is a Company Limited by Guarantee, first incorporated in 2003. In accordance with the Society's Memorandum of Association, each Company Member undertakes to contribute such amount as may be required, not exceeding £1, to the Company's assets if it should be wound up while he or she is a Company Member or within one year after he or she ceases to be so.

The Society is registered as a Charity, the Company Directors being the Charity's Trustees.

The Company Directors acting collectively are the Society's Executive.

The Executive hereby submits its report and financial statements for the year ending October 31<sup>st</sup> 2020.

## ***Organization and Objectives***

According to the articles, the Society is administered by the Executive, made up of minimum three and maximum ten Company Directors/Charity Trustees. Currently the Executive numbers eight Directors.

The ESCV has appointed a professional secretariat to handle administrative matters. This secretariat is Kenes Group, Calle Eraso, 36, 28028 Madrid, Spain

In accordance with Article 4 the Executive admits as 'ESCV Members' such persons and subjects them to such rights and obligations as it thinks fit. Such 'ESCV Members' are not Company Members for the purposes of the Articles and are not entitled to vote on any matter save where expressly provided in the Articles.

ESCV members of different European and other countries are represented by councilors, elected by each country's members according to procedures described in the Articles. The councilors acting collectively are the Council. The Council elects the Company Directors/Charity Trustees according to procedures described in the Articles.

The Society's objectives are to promote public health and to advance public education, in particular medical education, by:

- improving the knowledge of viruses, particularly as it relates to the diagnosis and management of viral diseases, their pathogenesis, natural history and prevention;
- improving diagnostic methods;
- promoting high standards in laboratory viral diagnosis through quality assessment activities and education; and
- promoting or developing for the benefit of the public the preparation and exchange of reference reagents."

## ***Reserves Policy***

The Executive has the policy to maintain sufficient funds to allow the Society to meet its objectives and obligations on a long-term basis, and to provide a measure of investment income. It is the objective of the Society to utilize fully each year's net income for its charitable activities.

## ***Review of Activities in 2019/2020***

### **Scientific Meetings**

- ESCV Workshop on Emerging Virus Infections, 23<sup>rd</sup>-24<sup>th</sup> January 2020, Vienna, Austria
- ESCV Virtual Meeting on Covid-19, 9<sup>th</sup> September 2020

### **Awards given at the ESCV 2020 Awards Ceremony (virtual)**

- Gardner Lectureship Award 2020 by Prof. Marion Koopmans.
- Abbott Award 2020 to Prof. Corinna Pietsch.
- BioMerieux Award 2020 to Prof. Judith Breuer.

### **Travel grants and fellowships given**

- 38 virologists received a travel grant to facilitate their attendance at the workshop in Vienna.
- 1 virologist received a travel grant to facilitate her attendance at the ESCV congress in Copenhagen, Denmark.

### **Training grants**

- None

### **Business Meetings held**

- ESCV Executive Meetings were held on 22<sup>nd</sup> January 2020 and 6<sup>th</sup> October 2020

### **Future Scientific Meetings planned**

- Award ceremony ESCV, 14<sup>th</sup> January 2021
- ESCV Virtual Spring Workshop – SARS-CoV-2 infection – laboratory response to pandemic, 22<sup>nd</sup> June 2021
- 23<sup>rd</sup> Annual Conference of the ESCV, 15<sup>th</sup> – 17<sup>th</sup> September 2021 (virtual)

-----  
Signed on behalf of the Executive (Company Directors),



Prof. Dr. Pam Vallely  
Company General Secretary



European Society for Clinical Virology  
(Limited by guarantee)

Report and Financial Statements

for the year ended 31 October 2020



## Statement of financial activities (incorporating the income and expenditure account)

Year ended 31 October 2020

	Note		Total 2020 £	Total 2019 £	Total 2018 £
Incoming Resources					
Incoming resources from operating activities in furtherance of the Society's activities					
Membership subscriptions	1		£17,734 (€20,605)	£4,931 (€5,505)	£16,511 (€18,350)
Sponsorship	2		£8,607 (€10,000)	£8,958 (€10,000)	£8,998 (€10,000)
Meetings contributions	3		£72,994 (€84,810)	£114,143 (€127,424)	£92,672 (€102,994)
Investment Income					
Income from listed investments	4		£0 (€0)	£125 (€139)	£602 (€669)
Total incoming resources			£99,335 (€115,415)	£128,157 (€143,068)	£118,783 (€132,013)
Resources expended					
Charitable expenditure					
Grants payable in furtherance of the Society's objects	5		£27,509 (€31,961.75)	£79,294 (€88,520)	£43,585 (€48,440)
Costs of activities in furtherance of the Society's objects	6		£17,575 (€20,420.40)	£57,025 (€63,660)	£30,245 (€33,614)
Costs of management & administration of the Society	7		£16,011 (€18,603.10)	£17,371 (€19,393)	£26,109 (€29,017)
Total resources expended			£61,095 (€70,985.25)	£151,653 (€169,298)	£99,939 (€111,071)
Net incoming/outgoing resources for the year			£38,240 (€44,429.75)	£-23,496 (€-26,230)	£18,844 (€20,941)

Other recognised gains and losses	8		£0	£0	-£5234
Transfer between Funds			-	-	-
Net movement in funds for the year			£38,240 (€44,429.75)	£-23,496 (€-26,230)	£-18,844 (€20,941)
Fund balances carried forward			£256,363 (€297,860.46)	£228,660 (€255,264)	£249,351 (€282,941)

## Balance Sheet

31st October 2019

		2020 £	2019 £	2018 £
<b>Current assets</b>				
Cash at Bank & in Hand	9	£256,363 (€297,860.46)	£228,660 (€255,264)	£249,351 (€282,941)
Receivables	10	£-	£-	£-
		£256,363 (€297,860.46)	£228,660 (€255,264)	£249,351 (€282,941)
<b>Creditors: amounts falling due within one year</b>				
Payables	11	£-	£-	£-
		£256,363 (€297,860.46)	£228,660 (€255,264)	£249,351 (€282,941)
<b>Net current assets</b>				
<b>Society Funds</b>				
General				
<b>Total funds</b>	12	£256,363 (€297,860.46)	£228,660 (€255,264)	£249,351 (€282,941)

The notes on pages 10 to 12 form part of these financial statements



### **Audit Exemption**

(a) For the year ended 31 October 2018 the company was entitled to exemption from audit under section 477(2) of the Companies Act 2006 relating to small companies.

(b) Members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

(c) The directors acknowledge their responsibility for:

i. ensuring the company keeps accounting records which comply with section 386; and

ii. preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the company;

(d) These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

**Approved by Executive on 27<sup>th</sup> May 2021 and signed on its behalf by  
Prof. Dr. Pam Vallely (company General Secretary ESCV)**



Prof. Pamela Vallely  
**Member of Executive**

## Notes to the Financial Statements

### 1. Membership Subscriptions

Society Membership subscriptions	£	12,945	15,040 €
Optional JCV subscriptions	£	4,789	5,565 €
<b>Total</b>			<b>20,605</b>
	<b>£</b>	<b>17,734</b>	<b>€</b>

### 2. Sponsorship

Sponsorship income was received for:

Abbott	£	2,152	2,500 €
BioMérieux	£	6,455	7,500 €
<b>Total</b>			<b>10,000</b>
	<b>£</b>	<b>8,607</b>	<b>€</b>

### 3. Meetings Contributions

VM Congresses – 22 <sup>nd</sup> Annual Congress ESCV	£		<b>84,810</b>
	<b>£</b>	<b>72,994</b>	<b>€</b>

### 4. Return on investments

General	£	0	0 €
---------	---	---	-----

### 5. Grants and awards

#### Travel grants to recipients

Viena	£	16,520	19,194.15 €
Copenhagen	£	661	767.60 €
<b>Total</b>			<b>19,961.75</b>
	<b>£</b>	<b>17,181</b>	<b>€</b>

#### Training Grants

Abbott Diagnostics Awards	£	2,152	2,500 €
Heine-Medin Award	£	1,721	2,000 €
BioMérieux Award	£	6,455	7,500 €
Gardner Award	£	0	0 €

<b>Total</b>	<b>£</b>	<b>10,328</b>	<b>12,000 €</b>
<b>TOTAL</b>	<b>£</b>	<b>27,509</b>	<b>31,961.75 €</b>

### 6. Costs of Activities in furtherance of the objectives of the Society

Purchase of Journal of Clinical Virology	£	1,784	2,072.38 €
--	---	-------	------------

Expenses of lecturers & venues at Scientific meetings	£ 15,791	18,348.02 €
	<b>£ 17,575</b>	<b>20,420.40 €</b>
7. Management and administration of the Society		
Administration costs	£ 11,247	13,068 €
Postal and Communications	£ -	0 €
Executive travel and accommodation	£ 4,260	4,949.58 €
Other	£ -	0 €
Bank charges	£ 504	585.52 €
	<b>£ 16,011</b>	<b>18,603.10 €</b>
8. Other Gains and Losses	£ -	0 €
9. Bank & Cash as at 31st October 2019		
BBVA Bank	£ 256,363	297,860.46 €
10. Receivables		
<b><u>TOTAL</u></b>	<b>£ -</b>	<b>- €</b>
11. Payables		
<b><u>TOTAL</u></b>	<b>£ -</b>	<b>- €</b>
12. Analysis of Net Assets between Reserves		
General in bank	£ -	0 €
Creditors	£ 256,363	297,860.46 €
<b><u>TOTAL</u></b>	<b>£ 256,363</b>	<b>297,860.46 €</b>





**Section A**

**Independent Examiner's Report**

**Report to the trustees/  
members of**

Charity Name  
European Society for Clinical Virology

**On accounts for the year  
ended**

31<sup>st</sup> October 2020

**Charity no  
(if any)** 1099537

**Set out on pages**

2 pages

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31/10/2020.

**Responsibilities and  
basis of report**

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent  
examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

*\* Please delete the words in the brackets if they do not apply.*

**Signed:**

**Date:** 21.07.2021

**Name:**

Susanne G. Dudman

**Relevant professional  
qualification(s) or body  
(if any):**

Senior Medical Officer

**Address:**

Oslo University Hospital

P.O.Box 4950 Nydalen

0424 Oslo, Norway



Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

**Give here brief details of any items that the examiner wishes to disclose.**

Nothing to disclose.